Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of Booster Dose of PoliorixTM Vaccine in Previously Vaccinated Toddlers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that their parent(s)/Legally Acceptable Representative(s) can and will comply with the requirements of the protocol.~* Subjects who received the complete three-dose primary vaccination course in study NCT01021293.~* Healthy male or female toddlers 18 to 24 months of age at the time of Visit 1 (Day 0).~* Written informed consent obtained from the parent(s)/ Legally Acceptable Representative(s) of the subject.~* Healthy subjects as established by medical history and clinical examination before entering into the study.~Exclusion Criteria:~* Child in care.~* Use of any investigational or non-registered product other than the study vaccine(s) within 30 days preceding the booster dose of study vaccine(s), or planned use during the study period.~* Chronic administration of immunosuppressants or other immune-modifying drugs within six months prior to Visit 1 (Day 0).~* Administration of immunoglobulins and/or any blood products within the 3 months preceding Visit 1 (Day 0) or planned administration during the study period.~* Administration of a vaccine not foreseen by the study protocol within 30 days of Visit 1 (Day 0) or planned administration during the study period.~* Concurrently participating in another clinical study, at any time during the study period, in which the subject has been or will be exposed to an investigational or a non-investigational product.~* Evidence of previous booster vaccination against poliomyelitis or the disease since the conclusion visit of Study NCT01021293.~* History of seizures or progressive neurological disease.~* Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.~* History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccine.~* Major congenital defects or serious chronic illness.~* Acute disease and/or fever at the time of enrolment.

- Gender: ALL
- Minimum Age: 18 Months
- Maximum Age: 24 Months
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): Subjects in this group will receive the GSK Biologicals' IPV vaccine at 18 months of age. Subjects will also receive a dose of DTPa/Hib (Infanrix+Hib) as part of the local standard of care.
- Group B (Type: ACTIVE_COMPARATOR): Subjects in this group will receive only a booster dose of GSK Biologicals' DTPa/Hib vaccine (Infanrix+Hib) as part of the local standard of care and will not be associated with any study endpoint.

Based on this trial design, predict the completion outcome and termination type (if applicable).